Rate My Professor Philip Davis

Davis contributes significantly to cardiovascular research, particularly in areas related to diabetic heart disease, cardiac remodeling, and regenerative therapies. His publications include co-authorship on 'Diabetes induces the activation of pro-ageing miR-34a in the heart' (Cell Death and Differentiation, 2018), 'Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in STEMI patients with diabetes' (Cardiovascular Diabetology, 2019), 'Frailty in Elderly Patients Undergoing Cardiac Surgery Increases Postoperative Complications' (Heart Lung and Circulation, 2020), 'Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications' (Cardiovascular Diabetology, 2021), 'Cardiac Progenitor Cells and Adipocyte Stem Cells from Same Patients Exhibit In Vitro Functional Differences' (International Journal of Molecular Sciences, 2022), 'Therapeutic knockdown of miR-320 improves deteriorated cardiac function in experimental diabetes' (Molecular Therapy Nucleic Acids, 2022), 'Combination of precipitation and size exclusion chromatography enables scalable purification of extracellular vesicles for clinical applications' (Nanotheranostics, 2023), and 'Ethnicity Is Associated With Differing Presentation and Outcomes of Patients Undergoing Cardiac Surgery' (Heart Lung and Circulation, 2023). These works, totaling around 22 peer-reviewed articles with over 440 citations, explore mechanisms such as microRNA dysregulation, stem cell therapies, extracellular vesicles, and frailty assessment in cardiac patients, advancing understanding of diabetes-induced cardiac pathologies and surgical outcomes.